Ingenium Signs INGENOtyping agreement with Max-Planck Institute

Published: 19-Dec-2003

German company Ingenium Pharmaceuticals has signed an agreement with the Max-Planck Institute of Immunobiology, located in Freiburg, Germany, whereby Ingenium will provide genetic mouse models for target genes to the Max-Planck Institute using its INGENOtyping platform.


German company Ingenium Pharmaceuticals has signed an agreement with the Max-Planck Institute of Immunobiology, located in Freiburg, Germany, whereby Ingenium will provide genetic mouse models for target genes to the Max-Planck Institute using its INGENOtyping platform.

This agreement brings to 10 the total number of INGENOtyping partnerships signed in 2003.

Ingenium has also signed an agreement with the German National Research Centre for Environment and Health (GSF) to access an additional murine tissue archive. This is the second in-licensing agreement with the GSF and, combined with Ingenium's internal production, will create the world's largest sperm archive, encompassing more than 10,000 individual samples, from which high value murine models can be produced.

The agreement with the GSF was negotiated with Ingenium's commercialisation arm, Ascenion.

  

You may also like